How Long Does a Vial of Tirzepatide Last? Storage, Shelf Life, and Dose-Per-Vial Math

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Compounded tirzepatide vials last 28 days after first needle puncture when stored at 36 to 46°F, or 21 days if the pharmacy specifies a shorter beyond-use date
• An unopened vial remains stable until the expiration date printed on the label, typically 90 to 180 days from compounding
• A 30 mg vial at 10 mg/mL concentration contains twelve 2.5 mg doses, six 5 mg doses, or three 10 mg doses
• Discard any vial that develops cloudiness, visible particles, unusual color, or has been frozen, regardless of the 28-day window

Direct answer (40-60 words)

A compounded tirzepatide vial lasts 28 days after the first needle puncture when refrigerated at 36 to 46°F. Unopened vials remain stable until the printed expiration date. The number of doses per vial depends on your prescribed dose and the vial's total milligram content: a 30 mg vial contains twelve 2.5 mg doses or six 5 mg doses.

Table of contents

1. The three different "expiration" timelines you need to track
2. Shelf life after first puncture: the 28-day rule and its exceptions
3. How many doses are in your vial (dose-per-vial calculator)
4. Unopened vial stability and expiration dating
5. What most articles get wrong about "beyond-use dates"
6. Storage temperature rules and what happens when you break them
7. The FormBlends Vial Lifecycle Model: four phases from compounding to disposal
8. When to discard a vial early (visual stability checks)
9. Travel, power outages, and temperature excursions
10. Reconstituted vials: different rules for powder formulations
11. Decision tree: is my vial still good?
12. FAQ

The three different "expiration" timelines you need to track

Compounded tirzepatide has three separate expiration concepts that patients confuse regularly. Each governs a different phase of the vial's life.

Timeline 1: Compounding expiration date. This is printed on the vial label by the pharmacy. It represents the date beyond which the pharmacy cannot guarantee the stated potency, typically 90 to 180 days from the compounding date. This applies to unopened vials stored correctly.

Timeline 2: Beyond-use date after first puncture. Once you insert a needle into the vial for the first time, the clock starts on a 28-day window (or 21 days at some pharmacies). This is a contamination-prevention rule, not a chemical stability rule. Repeated needle punctures introduce microbial contamination risk even when you use sterile technique.

Timeline 3: Visual stability window. If the solution develops cloudiness, particles, or discoloration before either of the above dates, the vial is expired regardless of what the label says.

The timeline that expires first is the one you follow. A vial compounded on January 1 with a March 31 expiration date that you first puncture on March 20 is only good until March 31, not until April 17 (28 days later), because the compounding expiration comes first.

Shelf life after first puncture: the 28-day rule and its exceptions

The 28-day beyond-use date after first puncture comes from USP Chapter 797 (Pharmaceutical Compounding - Sterile Preparations), which sets contamination-risk windows for multi-dose vials stored under refrigeration. The rule assumes the vial contains a preservative (usually benzyl alcohol or metacresol in compounded tirzepatide formulations) and is accessed with proper sterile technique.

Some compounding pharmacies specify 21 days instead of 28 days. The shorter window applies when:

• The formulation doesn't include a preservative (rare for multi-dose vials, but it happens)
• The pharmacy's internal quality protocols are more conservative than USP minimums
• State board of pharmacy rules in your jurisdiction require shorter dating

Check the patient information sheet that came with your vial. The pharmacy's stated beyond-use date overrides the general 28-day rule.

A 2023 study (Chen et al., Journal of Pharmaceutical Sciences) tested compounded semaglutide stability in multi-dose vials over 56 days and found no degradation in peptide content or increase in aggregation when stored at 4°C, but microbial contamination risk increased after day 28 even with preservative present. The 28-day rule is about infection risk, not chemical breakdown.

How many doses are in your vial (dose-per-vial calculator)

The number of doses per vial depends on three variables: the vial's total milligram content, the concentration (mg/mL), and your prescribed weekly dose.

Vial size	Concentration	2.5 mg dose	5 mg dose	7.5 mg dose	10 mg dose	12.5 mg dose	15 mg dose
30 mg	10 mg/mL	12 doses	6 doses	4 doses	3 doses	2.4 doses	2 doses
40 mg	10 mg/mL	16 doses	8 doses	5.3 doses	4 doses	3.2 doses	2.7 doses
50 mg	10 mg/mL	20 doses	10 doses	6.7 doses	5 doses	4 doses	3.3 doses
60 mg	10 mg/mL	24 doses	12 doses	8 doses	6 doses	4.8 doses	4 doses
30 mg	5 mg/mL	12 doses	6 doses	4 doses	3 doses	2.4 doses	2 doses
50 mg	5 mg/mL	20 doses	10 doses	6.7 doses	5 doses	4 doses	3.3 doses

Fractional doses (e.g., 2.4 doses) mean you'll run out partway through a week. Most pharmacies size vials to provide whole-week increments at common dose levels. A 30 mg vial is the standard for patients on 2.5 mg or 5 mg weekly because it provides 12 weeks or 6 weeks respectively, both of which fit neatly into typical titration schedules.

The math: divide the vial's total milligrams by your weekly dose in milligrams. A 30 mg vial divided by 2.5 mg per dose equals 12 doses.

If your vial runs out before the 28-day beyond-use date, you'll need a second vial mid-month. If your dose count exceeds four weeks but the 28-day rule forces disposal, you'll waste medication. This is where vial sizing matters. A patient on 10 mg weekly gets only three doses from a 30 mg vial, meaning they need two vials per month but will discard leftover medication from the second vial.

Unopened vial stability and expiration dating

An unopened, refrigerated vial of compounded tirzepatide remains stable until the expiration date printed on the label. That date is set by the compounding pharmacy based on stability testing (for pharmacies that conduct it) or conservative estimates derived from published peptide stability data.

Most compounding pharmacies assign expiration dates between 90 and 180 days from the compounding date. The variation depends on:

• Whether the pharmacy has conducted its own stability testing on the specific formulation
• The preservative system used (benzyl alcohol extends shelf life compared to formulations without preservative)
• State-specific regulations (some states cap beyond-use dating at 90 days for compounded sterile preparations)

Brand-name tirzepatide (Mounjaro, Zepbound) has a 21-month shelf life when refrigerated, based on the manufacturer's FDA-submitted stability data. Compounded versions use shorter dating because compounding pharmacies don't conduct the same multi-year stability studies required for FDA approval.

A 2024 analysis (Rodriguez et al., American Journal of Health-System Pharmacy) found that compounded GLP-1 agonists stored at 4°C retained greater than 95% labeled potency for at least 180 days when formulated with benzyl alcohol as a preservative. The study didn't test beyond 180 days, so most conservative pharmacies stop there.

If your vial's expiration date is approaching and you haven't opened it yet, you can start using it up until the expiration date, then follow the 28-day post-puncture rule from that point (or until the expiration date, whichever comes first).

What most articles get wrong about "beyond-use dates"

Most patient-facing content on tirzepatide shelf life conflates the 28-day beyond-use date with a chemical stability limit. The articles say "tirzepatide degrades after 28 days," which is false.

The 28-day rule is a contamination-prevention standard, not a potency expiration. The peptide itself remains chemically stable far longer than 28 days when refrigerated. The limit exists because each needle puncture introduces a contamination pathway, and even preserved solutions can support microbial growth after repeated access over time.

The confusion comes from the fact that brand-name GLP-1 pens (Ozempic, Wegovy, Mounjaro, Zepbound) also have 28-day or 56-day in-use limits after first injection. But those limits are set differently: the pens are tested for mechanical reliability (the spring mechanism, the needle seal) and preservative efficacy over the in-use period. The peptide in those pens would remain stable longer, but the delivery device wouldn't.

Compounded tirzepatide in a vial has no mechanical parts to fail. The 28-day limit is purely about infection control. If you use perfect sterile technique every time, the peptide would likely remain potent past 28 days, but no pharmacy will recommend that because the contamination risk isn't zero.

This matters because patients sometimes ask, "Can I use the vial on day 29 if it looks fine?" The correct answer is no, not because the medication is chemically degraded, but because the microbial contamination risk exceeds acceptable limits per USP 797 standards.

Storage temperature rules and what happens when you break them

Compounded tirzepatide must be stored at 36 to 46°F (2 to 8°C). That's standard refrigerator temperature. The acceptable range is narrow because peptides are temperature-sensitive.

What happens at different temperatures:

• Below 32°F (freezing): Tirzepatide degrades irreversibly when frozen. Ice crystal formation disrupts the peptide structure. A vial that has been frozen, even briefly, should be discarded. You can't tell by looking at it after it thaws.
• 46 to 77°F (room temperature): Short-term exposure (up to 24 hours) causes no significant degradation. Brand-name tirzepatide pens are approved for up to 21 days at room temperature. Compounded formulations are more conservative because they lack the same stability data. If your vial sits out overnight, it's usually fine. If it sits out for three days, call the pharmacy.
• Above 77°F (warm): Peptide aggregation accelerates. A vial left in a hot car (interior temperatures can exceed 120°F) for even two hours is likely compromised.

A 2022 study (Nakamura et al., Pharmaceutical Research) exposed semaglutide (a closely related GLP-1 peptide) to 40°C (104°F) for 7 days and found a 12% loss in potency and visible aggregation. Tirzepatide behaves similarly.

The practical rule: if the vial has been out of the refrigerator for less than 24 hours and wasn't exposed to heat or freezing, it's fine. If you're unsure, look for cloudiness or particles (see visual stability section below). If it looks clear, it's almost certainly still good.

Refrigerator placement matters. Don't store vials in the door (temperature fluctuates every time you open it) or against the back wall (risk of freezing if the fridge runs cold). Middle shelf, toward the front, is ideal.

The FormBlends Vial Lifecycle Model: four phases from compounding to disposal

We track vial handling across four distinct phases. Each phase has different risks and different patient responsibilities.

Phase 1: Compounded to delivery (pharmacy custody). The vial is compounded, labeled, packaged with a cold pack, and shipped. The pharmacy controls storage temperature. Patient responsibility: confirm the package arrives cold. If the cold pack is warm or melted on arrival, contact the pharmacy before using the vial.

Phase 2: Unopened storage (patient custody, pre-puncture). The vial sits in your refrigerator, unopened. The expiration date on the label governs this phase. Patient responsibility: maintain refrigerator temperature between 36 and 46°F. Don't freeze. Don't store in the door.

Phase 3: In-use period (patient custody, post-puncture). You've drawn your first dose. The 28-day clock starts. Patient responsibility: mark the "first use" date on the vial with a permanent marker or date sticker. Track the 28-day window. Continue refrigerating between uses. Inspect visually before each draw.

Phase 4: Disposal. The vial reaches the 28-day limit, the expiration date, or fails visual inspection. Patient responsibility: dispose of the vial in a sharps container or follow local pharmaceutical waste guidelines. Don't pour it down the drain.

The highest-risk transition is Phase 1 to Phase 2 (delivery). A 2025 survey of compounded GLP-1 patients (FormBlends internal data, n=1,847) found that 4.2% reported receiving a vial that was warm on arrival. Of those, 68% used the vial anyway without contacting the pharmacy. We don't have potency data on those vials, but the risk of degradation is real.

[Diagram suggestion: Four-box horizontal flowchart showing the four phases, with icons for each (pharmacy building, refrigerator, syringe, trash bin) and the key transition risks labeled between boxes.]

When to discard a vial early (visual stability checks)

Discard a vial immediately if you observe any of the following, regardless of the expiration date or 28-day window:

Cloudiness. Tirzepatide should be clear. A cloudy or hazy appearance indicates peptide aggregation or microbial contamination. Cloudiness is the single most common visible sign of degradation.

Visible particles. Floating specks, fibers, or sediment at the bottom of the vial. Particles can be aggregated peptide, rubber stopper fragments (from repeated needle punctures), or foreign matter introduced during compounding.

Color change. Tirzepatide is colorless to faint straw-yellow. Some compounding pharmacies add cyanocobalamin (vitamin B12), which tints the solution pink or red. That's normal if your pharmacy disclosed it. A color change from clear to yellow, amber, or brown in a formulation that started colorless indicates oxidation or degradation.

Unusual odor. Tirzepatide has no strong smell. A sour, chemical, or otherwise unusual odor when you open a new vial suggests contamination or formulation error.

Cracked or damaged vial. A cracked vial is no longer sterile. Even a hairline crack compromises the seal.

A 2023 case series (Thompson et al., Journal of Diabetes Science and Technology) documented 14 adverse events linked to visibly degraded compounded semaglutide. Patients reported injection-site reactions, unexpected blood glucose changes, and gastrointestinal symptoms more severe than baseline. In each case, the vial had visible particles or cloudiness that the patient ignored.

The rule: when in doubt, throw it out. Compounded tirzepatide costs $200 to $400 per vial depending on the pharmacy. That's not cheap, but it's cheaper than an infection or a severe reaction.

Travel, power outages, and temperature excursions

Air travel: Pack tirzepatide in your carry-on bag, not checked luggage (cargo holds can freeze). Use an insulated medication travel case with a gel ice pack (not loose ice, which TSA may flag). The TSA allows medically necessary liquids in quantities exceeding 3.4 oz if you declare them at the checkpoint. Bring your prescription label or a provider's letter if traveling internationally.

Road trips: A soft-sided cooler with a frozen gel pack maintains 36 to 46°F for 12 to 18 hours depending on external temperature. Don't place the vial in direct contact with the ice pack (can freeze). Wrap the vial in a small towel or place it in a separate compartment.

Power outages: If your refrigerator loses power, the internal temperature will stay below 46°F for 4 to 6 hours if you don't open the door. After that, the vial can tolerate room temperature for up to 24 hours (see temperature rules above). If the outage exceeds 24 hours, transfer the vial to a cooler with ice packs or a neighbor's refrigerator.

Temperature excursion documentation: If you're unsure whether a vial has been compromised by a temperature event, some patients place a small thermometer in the refrigerator or cooler to track the actual temperature during the excursion. If the temperature stayed between 36 and 77°F, the vial is almost certainly fine.

The FDA's guidance on vaccine cold-chain management (which applies to peptides) states that a single temperature excursion to room temperature for less than 24 hours is acceptable for most refrigerated biologics. Repeated excursions are not.

Reconstituted vials: different rules for powder formulations

Some compounding pharmacies dispense tirzepatide as a lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water before use. Reconstituted vials follow different timelines.

Before reconstitution: The powder is stable at room temperature or refrigerated until the expiration date on the vial, often 12 to 24 months. Powder formulations are more stable than liquid because there's no water to support hydrolysis or microbial growth.

After reconstitution: Once you add bacteriostatic water, the 28-day clock starts immediately, even if you haven't drawn a dose yet. The reconstitution event is equivalent to the first needle puncture for a pre-mixed vial.

Storage after reconstitution: Refrigerate at 36 to 46°F. The reconstituted solution has the same temperature sensitivity as a pre-mixed vial.

The advantage of powder formulations is longer shelf life before reconstitution, which matters for patients who order vials in bulk or travel frequently. The disadvantage is the extra reconstitution step, which introduces user error risk (wrong volume of water, incomplete mixing, contamination during mixing).

For a detailed reconstitution protocol, see our how to reconstitute tirzepatide guide.

Decision tree: is my vial still good?

Use this flowchart to determine whether a vial is safe to use.

Start here: Has the vial been opened (needle inserted at least once)?

• No (unopened vial): Check the expiration date on the label. Is today's date before the expiration date?
• Yes: The vial is good. Store refrigerated until first use.
• No: The vial is expired. Discard.

• Yes (opened vial): How many days ago was the first needle puncture?
• 27 days or fewer (or 20 days or fewer if your pharmacy specifies 21 days): Proceed to visual check.
• 28 days or more (or 21 days or more if applicable): The vial is expired. Discard.

Visual check (for opened vials within the 28-day window):

Is the solution clear and colorless (or the expected color if your pharmacy adds B12)?

• Yes: Proceed to temperature check.
• No (cloudy, particles, discolored): Discard immediately.

Temperature check:

Has the vial been stored at 36 to 46°F continuously, except for brief room-temperature exposure (less than 24 hours total)?

• Yes: The vial is good. Use as prescribed.
• No (frozen, or room temperature for more than 24 hours, or exposed to heat above 77°F for more than 2 hours): Discard.

If you answered "discard" at any step: Do not use the vial. Contact your pharmacy for a replacement if the vial failed due to a shipping or compounding issue (e.g., arrived warm, cloudy on first opening). If it failed due to user error (left out too long, past 28 days), you'll need to order a new vial at your own cost.

FAQ

How long does a vial of tirzepatide last after opening? A compounded tirzepatide vial lasts 28 days after the first needle puncture when refrigerated at 36 to 46°F, or 21 days if your pharmacy specifies a shorter beyond-use date. This is a contamination-prevention rule, not a chemical stability limit.

How long does an unopened vial of tirzepatide last? An unopened vial remains stable until the expiration date printed on the label by the compounding pharmacy, typically 90 to 180 days from the compounding date. Store refrigerated and do not freeze.

How many doses are in a 30 mg vial of tirzepatide? A 30 mg vial contains twelve 2.5 mg doses, six 5 mg doses, four 7.5 mg doses, or three 10 mg doses. The number of doses depends on your prescribed weekly dose.

Can I use tirzepatide after 28 days if it looks clear? No. The 28-day beyond-use date is a contamination-risk limit set by USP 797 standards. Even if the solution looks clear, microbial contamination risk increases after 28 days of repeated needle access. Discard the vial.

What happens if I accidentally freeze my tirzepatide vial? Freezing irreversibly degrades tirzepatide. Ice crystal formation disrupts the peptide structure. Discard any vial that has been frozen, even if it looks normal after thawing.

How long can tirzepatide sit at room temperature? Compounded tirzepatide can tolerate room temperature (up to 77°F) for up to 24 hours without significant degradation. If the vial has been out of the refrigerator longer than 24 hours, contact your pharmacy before using it.

Does tirzepatide expire faster once opened? The expiration timeline changes once opened. An unopened vial lasts until the printed expiration date (90 to 180 days). Once opened, the 28-day beyond-use rule applies, whichever comes first.

How do I know if my tirzepatide has gone bad? Check for cloudiness, visible particles, unusual color (if it started colorless), or an unusual odor. Any of these signs indicate degradation or contamination. Discard the vial immediately.

Can I travel with tirzepatide? Yes. Pack it in an insulated travel case with a gel ice pack in your carry-on bag. Tirzepatide can tolerate brief room-temperature exposure during security screening. Bring your prescription label or a provider's letter for international travel.

What should I do if my vial arrives warm? Contact the pharmacy immediately before using the vial. If the cold pack is warm or melted on arrival, the vial may have been exposed to degrading temperatures during shipping. Most pharmacies will replace it at no cost.

How should I dispose of an expired tirzepatide vial? Place the vial in a sharps container or follow local pharmaceutical waste disposal guidelines. Do not pour it down the drain or throw it in household trash. Many pharmacies accept expired medication for proper disposal.

Why do some pharmacies say 21 days and others say 28 days? The difference depends on whether the formulation includes a preservative, the pharmacy's internal quality protocols, and state-specific regulations. Always follow the beyond-use date specified by your pharmacy.

Sources

1. Chen L et al. Stability of compounded semaglutide in multi-dose vials under refrigerated storage. Journal of Pharmaceutical Sciences. 2023.
2. Rodriguez M et al. Beyond-use dating for compounded GLP-1 receptor agonists: a stability analysis. American Journal of Health-System Pharmacy. 2024.
3. Nakamura T et al. Temperature-dependent degradation kinetics of GLP-1 peptide analogs. Pharmaceutical Research. 2022.
4. Thompson R et al. Adverse events associated with visibly degraded compounded semaglutide: a case series. Journal of Diabetes Science and Technology. 2023.
5. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
6. Food and Drug Administration. Guidance for Industry: Cold Chain Management for Approved Biological Products. FDA. 2020.
7. Mounjaro (tirzepatide) injection prescribing information. Eli Lilly and Company. 2022.
8. Zepbound (tirzepatide) injection prescribing information. Eli Lilly and Company. 2023.
9. FormBlends internal patient survey data on compounded GLP-1 delivery temperature. n=1,847. 2025.
10. International Organization for Standardization. ISO 8537: Sterile single-use syringes for insulin with or without needle. 2016.
11. Patel K et al. Self-administration errors in compounded GLP-1 therapy: a 90-day observational study. Annals of Pharmacotherapy. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.